Vipadenant, also known as BIIB014, CEB-4520, is a potent, selective and orally available adenosine A2A receptor antagonist under development for for Parkinson's disease. Vipadenant demonstrates strong oral activity in commonly used models of Parkinson's disease. Vipadenant has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies.
臺州市科瑞生物技術有限公司
聯系商家時請?zhí)峒癱hemicalbook,有助于交易順利完成!
crene